• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Vfend (voriconazole) Tablets, Injection, and Oral Suspension

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2010


Summary View



Drug Interactions
  • Significant drug interactions that may require voriconazole dosage adjustment, or frequent monitoring of voriconazole-related adverse events/toxicity: Fluconazole (CYP2C9, CYP2C19 and CYP3A4 inhibitor)...